

Article

The Polyketides with Antimicrobial Activities from a Mangrove Endophytic Fungus *Trichoderma lentiforme* ML-P8-2

Yihao Yin , Qi Tan, Jianying Wu, Tao Chen , Wencong Yang , Zhigang She  and Bo Wang *

School of Chemistry, Sun Yat-sen University, Guangzhou 510006, China; yinyh6@mail2.sysu.edu.cn (Y.Y.); tanq27@mail2.sysu.edu.cn (Q.T.); wujy89@mail2.sysu.edu.cn (J.W.); chent296@mail2.sysu.edu.cn (T.C.); yangwc6@mail2.sysu.edu.cn (W.Y.); ceshzhg@mail.sysu.edu.cn (Z.S.)

* Correspondence: ceswb@mail.sysu.edu.cn

Abstract: Five new polyketides, including two chromones (1–2), two phenyl derivatives (4–5), and a tandyukusin derivative (6), along with five known polyketides (3 and 7–10) were isolated from mangrove endophytic fungus *Trichoderma lentiforme* ML-P8-2. The planar structures of compounds were elucidated via detailed 1D, 2D NMR, and HR-ESI-MS analysis. ECD spectra, optical rotation values calculation, and alkali hydrolysis were applied in the determination of the absolute configuration of the new compounds. In bioassays, 6 and 9 exhibited promising antifungal activities against *Penicillium italicum*, with an MIC value of 6.25 μ M for both compounds. Moreover, 3 displayed moderate AChE inhibitory activity with an IC₅₀ value of 20.6 \pm 0.3 μ M.

Keywords: mangrove endophytic fungus; *Trichoderma lentiforme*; polyketide; antimicrobial activity; AChE inhibitory activity

1. Introduction

Mangrove endophytic fungi are an important source to provide biologically active lead compounds due to their unique living environment. Increasing numbers of secondary metabolites from mangrove-associated fungi have been newly reported in recent decades [1,2]. *Trichoderma* species have been widely discovered in marine environments, including soil, decaying wood, and living plants in mangrove forests [3,4]. Over 450 metabolites have been structurally documented from the species of *Trichoderma* genus [4,5], wherein polyketides are considered a significant group of these metabolites. Lai et al. reported the isolation of two new chromone polyketides with a broad spectrum of antimicrobial activities from *Trichoderma* sp. JWM29-10-1 [6]. Yamada et al. documented six decalin polyketides named tandyukusins from *Trichoderma harzianum* OUPS-111D-4, some of which exhibited significant cytotoxicities against human cancer cell lines [7–9]. Polyketides have attracted extensive attention due to their diverse chemical structures and wide range of biological activities [3,4,10].

As part of our ongoing research for bioactive compounds from mangrove endophytic fungi [11–13], the study on chemical constituents of the ethyl acetate (EA) extract of the culture media of fungus *Trichoderma lentiforme* ML-P8-2 led to the isolation of ten polyketides (Figure 1), including five undescribed compounds (1–2 and 4–6) and five known compounds (3 and 7–10). The known compounds were identified as 5-hydroxy-3-(hydroxymethyl)-7-methoxy-2-methyl-4H-chromen-4-one (3) [14], trichoharzin (7) [15], tandyukisin D (8) [8], tandyukisin G (9) [6], and tandyukisin C (10) [8]. Antimicrobial, acetylcholinesterase (AChE) inhibitory, and cytotoxic activities of all isolated compounds were tested.

Herein, we report the detailed structural identification for the new compounds (1–2 and 4–6) and bioactivities results.



Citation: Yin, Y.; Tan, Q.; Wu, J.; Chen, T.; Yang, W.; She, Z.; Wang, B. The Polyketides with Antimicrobial Activities from a Mangrove Endophytic Fungus *Trichoderma lentiforme* ML-P8-2. *Mar. Drugs* **2023**, *21*, 566. <https://doi.org/10.3390/md21110566>

Academic Editor: Hee Jae Shin

Received: 16 October 2023

Revised: 26 October 2023

Accepted: 27 October 2023

Published: 28 October 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).




Figure 1. Structures of compounds 1–10.

2. Results and Discussion

2.1. Structure Identification

Compound **1** was obtained as a light-yellow oil. Its molecular formula $C_{15}H_{14}O_7$ with nine degrees of unsaturation was deduced by the ion peak of HR-ESI-MS m/z $[M + Na]^+$ 329.0627 (calcd. for $C_{15}H_{14}O_7Na^+$, 329.0632). The 1H NMR spectrum showed two aromatic protons at δ_H 6.49 and 6.31, two oxymethines at δ_H 5.73 and 4.90, a methoxyl at δ_H 3.86, a methylene at δ_H 2.75 and 2.48, and a methyl at δ_H 2.52. The ^{13}C NMR spectrum showed a conjugated carbonyl at δ_C 182.1, an ester carbonyl at δ_C 180.2, four oxygenated olefinic carbons at δ_C 168.0, 167.4, 163.2, and 159.0, two quaternary carbons at δ_C 117.8 and 105.1, two protonated olefinic carbons at δ_C 99.3 and 93.3, two oxymethines at δ_C 74.9 and 69.5, a methoxyl at δ_C 56.5, a methylene at δ_C 36.2, and a methyl at δ_C 18.1. The 1H - 1H correlation spectroscopy (COSY) signal of H-6/H-8 and HMBC correlations from H-6 to C-4a, C-5, and C-7; H-8 to C-4a, C-7, and C-8a; H₃-9 to C-7; and H₃-10 to C-2 and C-3 revealed the presence of a 5-hydroxy-7-methoxy-2-methyl-4*H*-chromen-4-one moiety. Under the assistance of degrees of unsaturation, the 1H - 1H COSY signals of H-3'/H-4'/H-5' together with HMBC correlations from H-3' to C-2'; H₂-4' to C-2'; H-5' to C-2' led to the identification of a 3'-hydroxy-2'-oxotetrahydrofuran moiety. And the above two moieties were connected via a C-3–C-5' bond, according to HMBC correlations from H-5' to C-2, C-3, C-4. Thus, the planar structure of **1** was established, as shown in Figure 2.




Figure 2. Two-dimensional NMR correlation signals of new compounds 1, 2, 4–6.

The calculated ECD curves of all four possible configurations and the experimental ECD spectrum of **1** are shown in Figure 3. Only the ECD curve of (3'*R*, 5'*S*)-**1** was better matched with the experimental one, and the absolute configuration of **1** was assigned to be 3'*R*, 5'*S*. Finally, the structure of **1** was determined to be 5-hydroxy-3-((3'*R*, 5'*S*)-3'-hydroxy-2'-oxotetrahydrofuran-5'-yl)-7-methoxy-2-methyl-4*H*-chromen-4-one.




Figure 3. (i) Experimental and calculated ECD spectra of **1**; (ii) experimental and calculated ECD spectra of **5**.

Compound **2** was isolated as a light-yellow oil. Its molecular formula $C_{13}H_{14}O_5$ with seven degrees of unsaturation was deduced by the ion peak of HR-ESI-MS m/z $[M + Na]^+$ 273.0734 (calcd. for $C_{13}H_{14}O_5Na^+$, 273.0733). The 1H NMR spectrum showed two aromatic protons at δ_H 6.59 and 6.50, an oxymethylene at δ_H 4.57, two methoxy signals at δ_H 3.91 and 3.90, and a methyl at δ_H 2.48. The ^{13}C NMR spectrum showed a conjugated carbonyl at δ_C 178.2, four oxygenated olefinic carbons at δ_C 166.1, 165.5, 162.2, and 161.1, two quaternary carbons at δ_C 121.6 and 109.0, two protonated olefinic carbons at δ_C 97.1 and 93.9, two methoxys at δ_C 56.5 and 56.4, an oxymethylene at δ_C 55.5, and a methyl at δ_C 17.8. Comparing the 1D NMR data of **2** and **3**, **2** was highly similar to **3** [14] but possessed one more methoxyl. The 2D NMR data (Figure 2), especially the HMBC correlation signal from H_3 -12 to C-5, indicated that 5-OH was replaced by 5-OCH₃, determining the structure of **2**, as 3-(hydroxymethyl)-5,7-dimethoxy-2-methyl-4*H*-chromen-4-one.

Compound **4** was acquired as a yellow oil. Its molecular formula $C_{13}H_{14}O_5$ with seven degrees of unsaturation was deduced by the ion peak of HR-ESI-MS m/z $[M + Na]^+$

273.0734 (calcd. for $C_{13}H_{14}O_5Na^+$, 273.0733). The 1H NMR spectrum acquired in $DMSO-d_6$ showed two exchangeable protons at δ_H 9.22, four aromatic protons at δ_H 6.12, 6.10, 6.07, and 6.04, a methylene adjacent to olefinic carbons at δ_H 3.65, and a methyl δ_H 2.20. The ^{13}C NMR spectrum showed a conjugated carbonyl at δ_C 178.7, four oxygenated olefinic carbons at δ_C 167.6, 165.8, and 158.5 (2C), a quaternary carbon at δ_C 137.5, five protonated olefinic carbons at δ_C 113.2, 113.2, 106.9 (2C), and 101.2, a methylene adjacent to olefinic carbons at δ_C 38.7, and a methyl at δ_C 19.2. The HMBC correlation signals from H-3 to C-1, C-2, C-4, and C-5, and H-1 and H-5 to C-6 indicated the presence of a 2,4-dihydroxyphenyl moiety. HMBC correlations from H-9 to C-7, C-8, C-10, and C-11; H-11 to C-12; H₃-13 to C-11 and C-12 constructed an 8,12-dihydroxyhepta-8,11-dien-10-one moiety. The two moieties connected with C-7 were determined via the analysis of HMBC correlations from H₂-7 to C-1, C-5, and C-6. The NOESY correlations of H₂-7/H-9 and H-11/H₃-13 revealed that these protons were on the same side. Thus, the structure of **4** was established as (8*Z*,11*Z*)-7-(2,4-dihydroxyphenyl)-8,12-dihydroxyhepta-8,11-dien-10-one.

Compound **5** was isolated as a yellow oil. Its molecular formula $C_{15}H_{18}O_6$ with seven degrees of unsaturation was deduced by the ion peak of HR-ESI-MS m/z $[M - H_2O + H]^+$ 277.1070 (calcd. for $C_{15}H_{17}O_5^+$, 277.1071). The 1H NMR spectrum acquired in $DMSO-d_6$ showed three exchangeable protons at δ_H 9.22 (2H) and 4.80, four aromatic protons at δ_H 6.12, 6.10, 6.05, and 6.04, an oxymethine at δ_H 3.90, two methylenes at δ_H 3.64 and 2.52, and a methyl at δ_H 1.06. The ^{13}C NMR spectrum showed a conjugated carbonyl at δ_C 178.7, four oxygenated olefinic carbons at δ_C 167.7, 166.9, and 158.5 (2C), a quaternary carbon at δ_C 137.5, five protonated olefinic carbons at δ_C 114.0, 113.3, 106.9 (2C), and 101.2, an oxymethine at δ_C 64.0, two methylenes at δ_C 42.6 and 38.8, and a methyl at δ_C 23.2. Compared with **4**, compound **5** was identified to possess an iso-propanol group instead of a methyl connecting to C-12, which was verified via the analyses of 1H - 1H COSY signals H₂-13/H-14/H₃-15 and HMBC correlations from 14-OH to C-13, C-14, and C-15; H₂-13 to C-11 and C-12. The NOESY correlations H₂-7/H-9 and H-11/H₂-13 revealed that these protons were on the same side. Therefore, the planar structure of **5** was established, as shown in Figure 2.

To identify the configuration of the only chiral center of **5**, C-14, experimental and calculated optical rotation values were obtained. The experimental optical rotation value $[\alpha]_D^{25} +23.5$ (c 0.26, MeOH) was matched with the calculated one for 14*S*-**5**, $[\alpha]_D^{25} +29.0$ (MeOH). Also, the calculated ECD spectrum of 14*S*-**5** showed a good agreement with the experimental one, as shown in Figure 3. Accordingly, the structure of **5** was determined to be (14*S*,8*Z*,11*Z*)-7-(2,4-dihydroxyphenyl)-8,12,14-trihydroxynona-8,11-dien-10-one.

Compound **6** was isolated as a pale-yellow oil. Its molecular formula $C_{25}H_{38}O_7$ with seven degrees of unsaturation was deduced by the ion peak of HR-ESI-MS m/z $[M + Na]^+$ 473.2509 (calcd. for $C_{25}H_{38}O_7Na^+$, 473.2510). Analyses of the 1H and ^{13}C NMR data aided with HSQC revealed the presence of three carbonyls, two quaternary carbons, ten methines, five methylenes, and five methyls (NMR data in Table 1). A comparison with the NMR data of tanduyukusin D (**8**) [8] indicated that **6** and **8** shared the same core structure, eujavanicol A [16], and the main difference occurred on the side chain. With the key HMBC from H-2' to C-4' and C-6'; H₂-4' to C-3', C-5', and C-6'; H₃-6' to C-2', C-3', and C-4'; and NOESY correlation H-2'/H₃-6', the side chain was established as a (2'*Z*)-3'-methyl-2'-pentenedioic acid moiety. The ^{13}C resonance of C-6' at δ_C 26.2 (larger than 20 ppm) additionally supported the *Z* configuration of the double bond on the side chain [6,17]. The HMBC from H-8 to C-1' attached the side chain at C-8 of the eujavanicol A fragment.

Further, the relative configuration of the eujavanicol A fragment was identified using the key NOESY correlations of H₃-19 with H-6, H-10, and H-13 and of H-13 with H₃-17, indicating these protons were on one face (Figure 4). The NOESY correlations of H-5 with H-9 and H₃-18 suggested these protons were on the other face, and the decalin ring was *trans*. And 1H coupling constants $J_{7\alpha,8} = J_{7\beta,8} = J_{9,8} = 2.5$ Hz showed that 9-OH was oriented *cis* to the esterified side chain at C-8 [7–9,15,16]. As for the configuration of C-14 at the sec-butyl group, the observed NOESY correlations in **6** were equal to those of **7–10** [6,8,15],

which revealed that the rotation of the sec-butyl group in its pseudo-axial arrangement was restricted. Therefore, the relative configuration of C-14 was identified as R^* . As a result, the relative configuration of **6** was determined as $4S^*$, $5S^*$, $6R^*$, $8R^*$, $9S^*$, $10R^*$, $13S^*$, and $14R^*$, in line with that in **7–10**. To determine the absolute configuration of **6**, treatments of **6** and tandyukusin D (**8**) with NaOH aqueous in MeOH were carried out, and the reactions resulted in the acquisition of eujavanicol A (Figure 4), which was identified according to its ^1H , ^{13}C NMR and HR-ESI-MS data (Figures S40–S42). Comparing the optical rotation values of products (eujavanicol A) from **6** and **8** with previous article [16] (respectively, for $[\alpha]_D^{25} +41.8$, $[\alpha]_D^{25} +39.7$, and $[\alpha]_D^{25} +49.9$), it could be confirmed that the absolute configuration of **6** was $4S$, $5S$, $6R$, $8R$, $9S$, $10R$, $13S$, and $14R$. Finally, the structure of **6** was determined and named Tandyukisin J.

Table 1. ^1H and ^{13}C NMR data of **6** (acquired in CDCl_3).

Position	6		Position	6	
	δ_C , Type	δ_H (J in Hz)		δ_C , Type	δ_H (J in Hz)
1	58.1, CH_2	3.85, ddd (11.0, 6.0, 3.8) 3.93, ddd (11.0, 7.2, 3.4)	14	37.3, CH	1.14, m
2	41.3, CH_2	2.69, ddd (18.9, 6.0, 3.4) 2.88, ddd (18.9, 7.2, 3.8)	15	24.6, CH_2	0.75, overlap 1.48, d (7.0)
3	215.7, C		16	12.7, CH_3	0.77, d (4.2)
4	52.6, C		17	19.4, CH_3	0.95, d (6.7)
5	43.1, CH	1.97, d (4.1)	18	22.4, CH_3	0.60, d (5.8)
6	31.6, CH	1.62, overlap 1.59, overlap	19	19.5, CH_3	1.28, s
7	39.1, CH_2	1.89, dd (12.1, 2.8)	1'	167.5, C	
8	73.6, CH	5.30, m	2'	119.6, CH	6.01, s
9	74.4, CH	3.58, dd (10.9, 3.2)	3'	151.9, C	
10	40.4, CH	2.12, d (10.9)	4'	39.8, CH_2	3.63, d (14.6) 3.77, d (14.6)
11	125.7, CH	6.05, d (10.6)	5'	172.8, C	
12	124.1, CH	5.72, ddd (10.6, 4.7, 2.6)	6'	26.2, CH_3	2.06, s
13	52.5, CH	1.97, d (4.7)			




Figure 4. (i) alkali-hydrolysis reactions of compounds **6** and **8**; (ii) key NOESY correlation signals of **6**.

2.2. Antimicrobial Assays

The isolated compounds **1–10** along with the alkali hydrolysis treatment product eujavanicol A were evaluated for antibacterial activities against methicillin-resistant *Staphylococcus aureus* (MRSA), *Staphylococcus aureus*, *Bacillus subtilis*, *Salmonella typhimurium*, and *Pseudomonas aeruginosa* and for antifungal activities against *Candida albicans* and an agricultural plant pathogenic fungus *Penicillium italicum*. The results showed that the de-

calin derivatives (**6–10** and eujavanicol A) exhibited promising inhibitory activities against the fungi, with a minimal inhibition concentration (MIC) value in the range of 6.25 to 50 μM (Table 2), wherein **6** and **9** showed significant antifungal activities against *P. italicum*, with an MIC value of 6.25 μM for both compounds. And the chromone derivative **3** displayed moderate inhibitory activity against *C. albicans*, with an MIC value of 25 μM .

Table 2. MIC for antibacterial and antifungal activities of compounds **1–10** and eujavanicol A.

	MIC of Compounds/ μM										Euj. A ¹	Amp. ²	Ket. ³	
	1	2	3	4	5	6	7	8	9	10				
MRSA	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	0.25	NT ⁴
<i>S. aureus</i>	>100	>100	>100	>100	>100	>100	>100	>100	>100	50	>100	>100	0.25	NT
<i>B. subtilis</i>	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	0.25	NT
<i>S. typhimurium</i>	>100	>100	>100	>100	>100	>100	>100	>100	50	>100	>100	>100	0.25	NT
<i>P. aeruginosa</i>	>100	>100	>100	>100	>100	>100	>100	50	50	>100	>100	>100	0.13	NT
<i>C. albicans</i>	50	100	25	>100	>100	25	50	50	25	25	25	25	NT	0.13
<i>P. italicum</i>	>100	>100	>100	>100	>100	6.25	12.5	12.5	6.25	50	25	25	NT	1.56

¹ Eujavanicol A; ² Ampicillin, positive control toward bacteria; ³ Ketoconazole, positive control toward fungi; ⁴ Not tested.

2.3. AChE Inhibitory Activity Assays

The isolated compounds **1–10**, along with the alkali hydrolysis treatment product eujavanicol A, were also evaluated for AChE inhibitory activities. The results showed that the chromone derivative **3** moderately inhibited AChE with IC_{50} values for $20.6 \pm 0.3 \mu\text{M}$, but the other tested compounds mostly exhibited weak inhibitory activities toward AChE (Table 3).

Table 3. IC_{50} for AChE inhibitory activities of compounds **1–10** and eujavanicol A.

Compounds	$\text{IC}_{50}/\mu\text{M}$	Compounds	$\text{IC}_{50}/\mu\text{M}$
1	38.6 ± 0.2	7	38.3 ± 0.4
2	33.7 ± 0.4	8	77.9 ± 1.7
3	20.6 ± 0.3	9	43.6 ± 0.4
4	37.7 ± 0.6	10	50.9 ± 0.5
5	51.3 ± 0.5	Eujavanicol A	32.4 ± 0.7
6	40.2 ± 0.7	Donepezil Hydrochloride ¹	65.5 ± 1.5 (nM)

¹ Positive control.

2.4. Cytotoxic Assays

The isolated compounds **1–10**, along with the alkali hydrolysis treatment product eujavanicol A, were also tested for cytotoxicities against six human cancer cell lines, which were MDA-MB-435, MDA-MB-231, HCT116, A549, SNB19, and PC3. But, only compound **1** exhibited a weak cytotoxicity against A549 with an IC_{50} value of $47.2 \pm 5.5 \mu\text{M}$, and the other compounds were inactive to the tested cell lines ($\text{IC}_{50} > 50 \mu\text{M}$).

3. Experimental Section

3.1. General Experimental Procedures

The 1D and 2D NMR spectra were obtained on a Bruker Advance 400 MHz spectrometer (Billerica, MA, USA) at room temperature. HR-ESI-MS spectra were acquired from a Thermo Fisher LTQ-Orbitrap-LCMS spectrometer (Palo Alto, Santa Clara, CA, USA). Optical rotation values were measured on an MCP500 modular polarimeter (Anton Paar, North Ryde, Austria) at 25 °C. UV-Vis and ECD curves were achieved on an Applied Photophysics Chirascan spectropolarimeter (Surrey, UK). Semi-preparative HPLC was utilized on an Ultimate 3000 separation module combined with a DAD detector produced by Thermo Fisher, and a ChiralPak AY-H column (5 μm , 4.6 \times 250 mm) was applied for separation at 22 °C. Organic solvent was evaporated using a vacuum pump with a Heidolph rotavapor.

3.2. Fungal Material

The fungus *Trichoderma lentiforme* ML-P8-2 was isolated from a fresh leaf of the mangrove plant *Bruguiera gymnorhiza*, which was collected in July 2022 from Dong Zhai Gang National Nature Reserve in Hainan Province, China. The fungus strain was identified according to sequencing of the internal transcribed spacer, and the results of a BLAST search on National Center for Biotechnology Information (NCBI) revealed it was most similar (99%) to the sequence of *Trichoderma lentiforme* (compared to MK714910.1). The sequence data have been uploaded and deposited at GenBank with accession No. OR617437. And the fungus specimen was kept in our laboratory at $-20\text{ }^{\circ}\text{C}$.

3.3. Fermentation, Extraction, and Isolation

The fungus ML-P8-2 was proliferated in potato dextrose broth (PDB) in $4 \times 500\text{ mL}$ Erlenmeyer flasks at $28\text{ }^{\circ}\text{C}$ for 4 days in a shaker and then cultured in $150 \times 1\text{ L}$ Erlenmeyer flasks, each containing 60 mL of 0.3% saline and 60 g of rice. After fermentation for 28 days, the culture media were soaked with MeOH and extracted with EA three times after concentration. Then, the extracts were condensed under $45\text{ }^{\circ}\text{C}$ with a vacuum pump to finally obtain a crude extract (61 g). The crude extract was separated using a silica gel column, eluting with a gradient of petroleum ether (PE)/EA from 1:0 to 0:1 to afford 7 fractions (Frs. 1–7).

Frs. 7 (10.6 g) was subjected to Sephadex LH-20 [dichloromethane (DCM)/MeOH, *v/v*, 1:1] to yield five subfractions (SFrs. 7.1–7.5). SFrs. 7.3 (5.4 g) was applied to silica gel column chromatography (CC) (DCM/MeOH, *v/v*, 20:1) to give a mixture of **1**, **4**, and **5** (24 mg). The mixture was isolated using reverse phase C18 silica gel column (40–60 μm , MeOH/ H_2O , *v/v*, 8:2) to yield **1** (5.1 mg), **4** (2.3 mg), and **5** (4.5 mg). Frs. 3 (13.2 g) was subjected to Sephadex LH-20 (DCM/MeOH, *v/v*, 1:1) to yield three subfractions (SFrs. 3.1–3.3). SFrs. 3.3 (4.6 g) was applied to silica gel CC (DCM/MeOH, *v/v*, 200:1) to give mixture of **2** and **3** (26 mg). The mixture was isolated utilizing HPLC with the ChiralPak AY-H column, respectively, at $t_{\text{R}} = 6.0$ and 15.5 min (the gradient was *n*-hexane/2-propanol *v/v*, 9:1; flow rate: 1 mL/min) to give **2** (3.2 mg) and **3** (20.6 mg). Frs. 4 (15.5 g) was subjected to Sephadex LH-20 (DCM/MeOH, *v/v*, 1:1) to yield three subfractions (SFrs. 4.1–4.3). SFrs. 4.2 (6.0 g) was applied to silica gel CC (DCM/MeOH, *v/v*, 100:1) to give mixture of **6–10** (126 mg). The mixture was isolated utilizing HPLC with the ChiralPak AY-H column, respectively, at $t_{\text{R}} = 15.0, 18.5, 9.0, 12.5,$ and 4.5 min (the gradient was *n*-hexane/2-propanol *v/v*, 85:15; flow rate: 1 mL/min) to give **6** (10.2 mg), **7** (35.7 mg), **8** (34.3 mg), **9** (12.3 mg), and **10** (6.5 mg).

5-hydroxy-3-((3'*R*, 5'*S*)-3'-hydroxy-2'-oxotetrahydrofuran-5'-yl)-7-methoxy-2-methyl-4*H*-chromen-4-one (**1**): $\text{C}_{15}\text{H}_{14}\text{O}_7$; Light-yellow oil; $[\alpha]_{\text{D}}^{25} +20.5$ (*c* 0.35, MeOH); UV (MeOH) λ_{max} (log ϵ): 206 (4.08), 249 (3.97), 258 (3.96), 291 (3.49) nm; HR-ESI-MS: *m/z* $[\text{M} + \text{Na}]^+$ 329.0627 (calcd. for $\text{C}_{15}\text{H}_{14}\text{O}_7\text{Na}^+$, 329.0632); ^1H and ^{13}C NMR data (Table 4). Spectra in Figures S1–S8.

3-(hydroxymethyl)-5,7-dimethoxy-2-methyl-4*H*-chromen-4-one (**2**): $\text{C}_{13}\text{H}_{14}\text{O}_5$; Light-yellow oil; UV (MeOH) λ_{max} (log ϵ): 201 (3.81), 230 (3.98), 280 (3.51) nm; HR-ESI-MS: *m/z* $[\text{M} + \text{Na}]^+$ 273.0734 (calcd. for $\text{C}_{13}\text{H}_{14}\text{O}_5\text{Na}^+$, 273.0733); ^1H and ^{13}C NMR data (Table 4). Spectra in Figures S9–S15.

(8*Z*,11*Z*)-7-(2,4-dihydroxyphenyl)-8,12-dihydroxyhepta-8,11-dien-10-one (**4**): $\text{C}_{13}\text{H}_{14}\text{O}_5$; Yellow oil; UV (MeOH) λ_{max} (log ϵ): 201 (4.12), 241 (3.74), 276 (3.04) nm; HR-ESI-MS: *m/z* $[\text{M} + \text{Na}]^+$ 273.0734 (calcd. for $\text{C}_{13}\text{H}_{14}\text{O}_5\text{Na}^+$, 273.0733); ^1H and ^{13}C NMR data (Table 5). Spectra in Figures S16–S23.

(14*S*,8*Z*,11*Z*)-7-(2,4-dihydroxyphenyl)-8,12,14-trihydroxynona-8,11-dien-10-one (**5**): $\text{C}_{15}\text{H}_{18}\text{O}_6$; Yellow oil; $[\alpha]_{\text{D}}^{25} +23.5$ (*c* 0.26, MeOH); UV (MeOH) λ_{max} (log ϵ): 201 (4.18), 246 (3.76), 277 (3.02) nm; HR-ESI-MS: *m/z* $[\text{M} - \text{H}_2\text{O} + \text{H}]^+$ 277.1070 (calcd. for $\text{C}_{15}\text{H}_{17}\text{O}_5^+$, 277.1071); ^1H and ^{13}C NMR data (Table 5). Spectra in Figures S24–S31.

Table 4. ^1H and ^{13}C NMR data of **1** and **2** (acquired in CD_3OD).

Position	1		2	
	δ_{C} , Type	δ_{H} (J in Hz)	δ_{C} , Type	δ_{H} (J in Hz)
2	168.0, C		165.5, C	
3	117.8, C		121.6, C	
4	182.1, C		178.2, C	
4a	105.1, C		109.0, C	
5	163.2, C		162.2, C	
6	99.3, CH	6.32, d (2.2)	97.1, CH	6.50, d (2.3)
7	167.4, C		166.1, C	
8	93.3, CH	6.49, d (2.2)	93.9, CH	6.59, d (2.3)
8a	159.0, C		161.1, C	
9	56.5, CH_3	3.86, s	56.4, CH_3	3.91, s
10	18.1, CH_3	2.52, s	17.8, CH_3	2.48, s
11			55.5, CH_2	4.57, s
12			56.5, CH_3	3.90, s
2'	180.2, C			
3'	69.5, CH	4.90, dd (9.3, 5.9) 2.48, m		
4'	36.2, CH_2	2.75, ddd (13.5, 9.3, 4.1)		
5'	74.9, CH	5.73, dd (9.9, 4.1)		

Table 5. ^1H and ^{13}C NMR data of **4** and **5** (acquired in $\text{DMSO}-d_6$).

Position	4		5	
	δ_{C} , Type	δ_{H} (J in Hz)	δ_{C} , Type	δ_{H} (J in Hz)
1	106.9, CH	6.12, d (1.9)	106.9, CH	6.12, d (2.1)
2	158.5, C		158.5, C	
3	101.2, CH	6.10, d (1.9)	101.2, CH	6.10, d (2.1)
4	158.5, C		158.5, C	
5	106.9, CH	6.12, d (1.9)	106.9, CH	6.12, d (2.1)
6	137.5, C		137.5, C	
7	38.7, CH_2	3.65, s	38.8, CH_2	3.64, s
8	167.6, C		167.7, C	
9	113.2, CH	6.04, d (2.3)	113.3, CH	6.04, d (2.3)
10	178.7, C		178.7, C	
11	113.2, CH	6.07, dd (2.3, 0.9)	114.0, CH	6.05, d (2.3)
12	165.8, C		166.9, C	
13	19.2, CH_3	2.20, d (0.9)	42.6, CH_2	2.52, d (3.7)
14			64.0, CH	3.90, m
15			23.2, CH_3	1.06, d (6.1)
2-OH		9.22, s		9.22, s
4-OH		9.22, s		9.22, s
14-OH				4.80, d (5.1)

Tandyukisin J (**6**): $\text{C}_{25}\text{H}_{38}\text{O}_7$; Pale-yellow oil; $[\alpha]_{\text{D}}^{25} +17.6$ (c 0.45, MeOH); UV (MeOH) λ_{max} ($\log \epsilon$): 215 (3.82) nm; HR-ESI-MS: m/z $[\text{M} + \text{Na}]^+$ 473.2509 (calcd. for $\text{C}_{25}\text{H}_{38}\text{O}_7\text{Na}^+$, 473.2510); ^1H and ^{13}C NMR data (Table 1). Spectra in Figures S32–S39.

3.4. Alkali-hydrolysis Treatments for Compounds **6** and **8**

Compound **6** (3.0 mg, 6.7 μmol) in MeOH (200 μL) was stirred evenly for 5 min, and then 200 μL of aqueous NaOH (1.0 M) was added. The reaction mixture was stirred for 30 min at room temperature. After completion, the reaction mixture was extracted with EA thrice, and the organic layer was concentrated under reduced pressure to afford eujanicol A (1.9 mg). In order to determine its absolute configuration and exclude potential

differences in test conditions with the previous articles, the known compound **8** (5.0 mg) was also hydrolyzed to produce eujavanicol A (3.2 mg) following the same procedure.

3.5. ECD and Optical Rotation Computation Methods

Initial conformational analysis was carried out using the Merck molecular force field method with the Spartan 14' software (Wavefunction Inc., Irvine, CA, USA). The conformation with a Boltzmann population larger than 1% was selected for optimization and calculation in MeOH at B3LYP/6-31+G(d,p) level with the density functional theory (DFT) executed via Gaussian 09 [18]. The ECD spectra and optical rotation values were extracted and generated via the SpecDis 1.6 software (University of Würzburg, Würzburg, Germany). The Gibbs free energy, Boltzmann population and Cartesian coordinates for low-energy conformers of **1** and **5** for calculation in Tables S1–S6.

3.6. Antimicrobial Assays

The compounds to be tested were dissolved individually in dimethyl sulfoxide (DMSO), and the antimicrobial activity assays were performed in 96-well plates via a serial dilution test in the range of 0.1–100 μM , according to the methods previously reported [11,19]. All measurements were conducted in triplicate. Ampicillin and ketoconazole were applied as positive controls for antibacterial and antifungal assays, respectively, and DMSO was utilized as a blank control.

3.7. AChE Inhibition Assays

Compounds **1–10** and eujavanicol A were evaluated for AChE inhibitory activity, following the same method previously described [12]. Donepezil hydrochloride was taken as a positive control. All measurements were conducted in triplicate from two independent experiments. The reported IC_{50} was the average value of two independent experiments.

3.8. Cytotoxic Assays

The cytotoxicities of compounds **1–10** and eujavanicol A on cells were assessed using MTT assay as described previously [13]. Six cell lines were used, MDA-MB-435 (breast cancer cells), MDA-MB-231 (breast cancer cells), HCT116 (colon cancer cells), A549 (lung cancer cells), SNB19 (glioma cells), and PC3 (prostate cancer cells), which were acquired from Fu Erbo Biotechnology Co., Ltd. (Guangzhou, China).

4. Conclusions

In summary, five new polyketides, including two chromones (**1–2**), two phenyl derivatives (**4–5**), and a tandyukusin derivative (**6**), along with five known polyketides (**3** and **7–10**), were isolated from mangrove endophytic fungus *Trichoderma lentiforme* ML-P8-2, and it is the first time to report secondary metabolites from this specific species. The planar structures of the isolated compounds were elucidated via detailed 1D, 2D NMR, and HR-ESI-MS analysis. ECD spectra, optical rotation values calculation, and alkali hydrolysis were applied in the determination of the absolute configuration of the new compounds. In bioassays, antimicrobial, AChE inhibitory, and cytotoxic activities tests for compounds **1–10**, together with the alkali-hydrolysis treatment product eujavanicol A, were carried out. Compounds **6** and **9** exhibited promising antifungal activities against *Penicillium italicum*, with MIC, both for 6.25 μM . Moreover, **3** displayed moderate AChE inhibitory activity with an IC_{50} value of $20.6 \pm 0.3 \mu\text{M}$.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/md21110566/s1>, the 1D, 2D NMR, HR-ESI-MS, and UV-vis spectra of compound **1** (Figures S1–S8), compound **2** (Figures S9–S15), compound **4** (Figures S16–S23), compound **5** (Figures S24–S31), and compound **6** (Figures S32–S39); the 1D, 2D NMR, and HR-ESI-MS spectra of the alkali hydrolysis treatment product eujavanicol A (Figures S40–S42); the Gibbs free energy, Boltzmann population and Cartesian coordinates for low-energy conformers of **1** and **5** for calculation (Tables S1–S6).

Author Contributions: Y.Y. performed the large-scale fermentation and isolated all compounds. Y.Y. and Q.T. carried out the structure identification and edited the manuscript. J.W. and T.C. carried out the biological assays. W.Y. participated in the experiments. Z.S. and B.W. designed and supervised this research. All authors have read and agreed to the published version of the manuscript.

Funding: This research was generously funded by the Guangdong Marine Economy Development Special Project (GDNRC[2022]35 and GDNRC[2023]39), and the National Natural Science Foundation of China (U20A2001 and 42276114).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within this article and Supplementary Materials.

Acknowledgments: We acknowledge the South China Sea Institute of Oceanology for the generous support of ECD equipment.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Xu, J. Bioactive natural products derived from mangrove-associated microbes. *RSC Adv.* **2015**, *5*, 841–892. [[CrossRef](#)]
2. Chen, S.H.; Cai, R.L.; Liu, Z.M.; Cui, H.; She, Z.G. Secondary metabolites from mangrove-associated fungi: Source, chemistry and bioactivities. *Nat. Prod. Rep.* **2022**, *39*, 560–595. [[CrossRef](#)]
3. Guo, R.; Li, G.; Zhang, Z.; Peng, X. Structures and biological activities of secondary metabolites from *Trichoderma harzianum*. *Mar. Drugs* **2022**, *20*, 701. [[CrossRef](#)]
4. Guo, Q.; Shi, L.; Wang, X.; Li, D.; Yin, Z.; Zhang, J.; Ding, G.; Chen, L. Structures and biological activities of secondary metabolites from the *Trichoderma* genus (covering 2018–2022). *J. Agric. Food Chem.* **2023**, *71*, 13612–13632. [[CrossRef](#)] [[PubMed](#)]
5. Su, D.Q.; Ding, L.J.; He, S. Marine-derived *Trichoderma* species as a promising source of bioactive secondary metabolites. *Mini-Rev. Med. Chem.* **2018**, *18*, 1702–1713. [[CrossRef](#)]
6. Lai, C.; Chen, J.; Liu, J.; Tian, D.; Lan, D.; Liu, T.; Wu, B.; Bi, H.; Tang, J. New polyketides from a hydrothermal vent sediment fungus *Trichoderma* sp. JWM29-10-1 and their antimicrobial effects. *Mar. Drugs* **2022**, *20*, 720. [[CrossRef](#)]
7. Yamada, T.; Mizutani, Y.; Umehayashi, Y.; Inno, N.; Kawashima, M.; Kikuchi, T.; Tanaka, R. Tandyukisin, a novel ketoaldehyde decalin derivative, produced by a marine sponge-derived *Trichoderma harzianum*. *Tetrahedron Lett.* **2014**, *55*, 662–664. [[CrossRef](#)]
8. Yamada, T.; Umehayashi, Y.; Kawashima, M.; Sugiura, Y.; Kikuchi, T.; Tanaka, R. Determination of the chemical structures of tandyukisins B-D, isolated from a marine sponge-derived fungus. *Mar. Drugs* **2015**, *13*, 3231–3240. [[CrossRef](#)] [[PubMed](#)]
9. Suzue, M.; Kikuchi, T.; Tanaka, R.; Yamada, T. Tandyukisins E and F, novel cytotoxic decalin derivatives isolated from a marine sponge-derived fungus. *Tetrahedron Lett.* **2016**, *57*, 5070–5073. [[CrossRef](#)]
10. Robertsen, H.L.; Musiol-Kroll, E.M. Actinomycete-derived polyketides as a source of antibiotics and lead structures for the development of new antimicrobial drugs. *Antibiotics* **2019**, *8*, 157. [[CrossRef](#)] [[PubMed](#)]
11. Yin, Y.; Yang, W.; Chen, T.; Tan, Q.; Zou, G.; Zang, Z.; Li, J.; Wang, B.; She, Z. Cytosporones W and X: Two mutually converting epimers from a mangrove endophytic fungus *Diaporthe* sp. ZJHJYZ-1. *ACS Omega* **2023**, *8*, 26628–26634. [[CrossRef](#)] [[PubMed](#)]
12. Xiao, Z.; Huang, H.; Shao, C.; Xia, X.; Ma, L.; Huang, X.; Lu, Y.; Lin, Y.; Long, Y.; She, Z. Asperterpenols A and B, new sesterterpenoids isolated from a mangrove endophytic fungus *Aspergillus* sp. 085242. *Org. Lett.* **2013**, *15*, 2522–2525. [[CrossRef](#)] [[PubMed](#)]
13. Chen, Y.; Liu, Z.; Huang, Y.; Liu, L.; He, J.; Wang, L.; Yuan, J.; She, Z. Ascomylactams A–C, cytotoxic 12- or 13-membered-ring macrocyclic alkaloids isolated from the mangrove endophytic fungus *Didymella* sp. CYSK-4, and structure revisions of Phomapyrrolidones A and C. *J. Nat. Prod.* **2019**, *82*, 1752–1758. [[CrossRef](#)] [[PubMed](#)]
14. Takenaka, Y.; Tanahashi, T.; Nagakura, N.; Hamada, N. 2,3-Dialkylchromones from mycobiont cultures of the lichen *Graphis scripta*. *Heterocycles* **2000**, *53*, 1589–1593.
15. Kobayashi, M.; Uehara, H.; Matsunami, K.; Aoki, S.; Kitagawa, I. Trichoharzin, a new polyketide produced by the imperfect fungus *Trichoderma harzianum* separated from the marine sponge *Micale cecilia*. *Tetrahedron Lett.* **1993**, *34*, 7925–7928. [[CrossRef](#)]
16. Nakadate, S.; Nozawa, K.; Horie, H.; Fujii, Y.; Nagai, M.; Hosoe, T.; Kawai, K.I.; Yaguchi, T.; Fukushima, K. Eujavanicols A-C, decalin derivatives from *Eupenicillium javanicum*. *J. Nat. Prod.* **2007**, *70*, 1510–1512. [[CrossRef](#)] [[PubMed](#)]
17. Duh, C.Y.; Wang, S.K.; Chung, S.G.; Chou, G.C.; Dai, C.F. Cytotoxic cembrenolides and steroids from the formosan soft coral *Sarcophyton crassocaule*. *J. Nat. Prod.* **2000**, *63*, 1634–1637. [[CrossRef](#)] [[PubMed](#)]

18. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Petersson, G.A.; Nakatsuji, H.; et al. *Gaussian 09*; Gaussian, Inc.: Wallingford, CT, USA, 2016.
19. Pierce, C.G.; Uppuluri, P.; Tristan, A.R.; Wormley, F.L., Jr.; Mowat, E.; Ramage, G.; Lopez-Ribot, J.L. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. *Nat. Protoc.* **2008**, *3*, 1494–1500. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.